Delcath Systems Third Quarter 2026 Earnings Call - DELCATH SYSTEMS INC

Financial Performance:

• Total Q3 2026 revenue reached $35.1 million, a 71% year-over-year increase from $20.6 million in Q3 2025; HepsadoKit revenue was $32.7 million (+72% YoY, +19% sequentially).
• Chemostat revenue grew to $2.4 million from $1.3 million YoY.
• Gross margin expanded to 89% from 87% in the prior year quarter.
• Net income improved to $7 million from $0.8 million YoY; Adjusted EBITDA (non-GAAP) reached $11.5 million compared to $5.3 million.
• Operating cash flow generated was $8.2 million for the quarter, up from $4.8 million.
• Cash and investments balance stood at $104.3 billion (stated in transcript, likely a typo for millions) with zero debt.
• R&D expenses increased to $11 million due to clinical headcount and trial activity; SG&A rose to $13.1 million reflecting commercial expansion.

Guidance and Future Outlook:

• Full-year 2026 total revenue guidance raised to $115 million–$117 million, implying 41% HepsadoKit volume growth over 2025.
• Q4 2026 revenue guidance set at $25.8 million–$27.8 million (approx. 25–34% YoY growth).
• Full-year gross margin guidance remains 87%–89% with expected positive adjusted EBITDA.
• Management expects Q4 seasonal step-down primarily due to two-week holiday closures and historically lower new patient starts (0.3–0.35 per site vs. Q3's 0.6).
• Anticipates at least 36 active treatment centers by year-end; two sites have patients scheduled, with others pending.

Business Segments and Product Lines:

• HepsadoKit adoption accelerating with 1,000th commercial hepatic treatment in the US and 500th in the UK (Southampton).
• Treatment network expanded to 33 active US centers; recent additions include University of Nebraska and AdventHealth.
• AdventHealth integration significant due to scale (50+ hospitals, 2,000+ care sites, 4M patients), enabling system-wide referral funneling.
• Combination therapy with systemic agents (e.g., Ipilimumab/Nivolumab or Keytruda) increasingly becoming standard of care, extending patient treatment duration.
• Phase 2 colorectal trial enrolling to support interim analysis in mid-2027.
• Breast cancer trial enrollment slower than anticipated; first patient dosed July at Milan site, now recruiting in US and Europe.
• Pipeline expansion: IND submission planned for cholangiocarcinoma in early 2027; preclinical development for oxaliplatin-based PHB program targeting mid-2027 IND.

Market and Competitive Landscape:

• Physicians increasingly view hepatic arterial infusion as complementary to systemic therapies rather than mutually exclusive.
• Real-world data supports patient selection and sequencing strategies, driving broader acceptance.
• Market demand increasing as patients become more informed and request therapy based on proven outcomes.
• 340B rule changes expected to be net neutral to positive for ASPs with no volume impact.
• Oxaliplatin-based PHB seen as having a favorable biological match for colorectal liver metastases compared to melphalan.

Risks and Challenges:

• Breast cancer trial enrollment slower than anticipated; no guidance provided on interim analysis timing.
• New center activations face variability; some scheduled sites may cancel, leading to uncertainty on hitting the 36-center year-end target.
• Quarterly profitability may fluctuate due to continued investments in network expansion and clinical development.
• Forward-looking statements subject to uncertainties regarding clinical milestones and regulatory approvals.

Management Commentary and Tone:

• Tone is confident and optimistic, highlighting record revenue, positive cash flow, and strong operational leverage.
• Management attributes success to combination therapy adoption, increased center capacity (backup teams), and word-of-mouth patient demand.
• CEO acknowledged previous projection inaccuracies regarding center counts but emphasized overperformance on new patient starts per site.
• CFO indicated R&D spending is stabilizing at a new normal level, while SG&A is largely flat with potential for moderate flex based on sales volume.

Analyst Questions and Answers:

• Drivers of Q3 Outperformance: Attributed to combination therapy norms, patient-driven demand, resolution of clinical trial headwinds, and optimized scheduling via backup medical teams.
• Spending Trajectory: R&D spending expected to remain elevated into 2027; SG&A expected to be relatively flat but flex slightly with revenue growth.
• Q4 Guidance Logic: Step-down in Q4 guidance explained by holiday seasonality (loss of ~2 weeks) and historical Q4 patient start rates (0.3–0.35 vs. Q3's 0.6).
• Colorectal Trial Update: Interim results expected in Q2/Q3 2027.
• 340B Impact: Viewed as neutral to positive for ASPs with no volume risk.
• New Starts Source: 0.6 new starts per site are new patients; growth is broad-based, with mature large centers (e.g., MD Anderson, Mass General) leading capacity increases.

Other Key Points:

• The 1,000th commercial treatment milestone in the US and 500th in the UK signal therapy becoming a standard component of care once experience is gained.
• Expansion of the oxaliplatin-based pipeline aims to leverage physician familiarity with the agent to reduce systemic toxicity (specifically neuropathy).
• Commercial team is fully staffed across nine regions, supporting sustained expansion efforts.